In addition, considering the role of bFGF in resistance to anti-VEGF therapy, we speculate that targeting the Gli1-bFGF signaling pathway might be a potential therapeutic strategy for overcoming resistance to antiangiogenic and anti-VEGF therapies in NSCLC. Here, GLI1 is linked to non-small cell lung carcinoma.